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background: Ischemia reperfusion injury (IRI) is an exogenous Ag-independent innate immune-dominated event that remains one of the most 
understudied yet critical problems in clinical organ transplantation and after intervention for myocardial infarction. IRI causes approximately 10% of 
transplant graft failure, contributing to a higher incidence of acute and chronic rejection and to a shortage of donor organs. Caspase-1/Interleukin-1 
converting enzyme proteolytically cleaves precursor forms of inflammatory cytokines, interleukin-1β (IL-1b) and interleukin 18, into active peptides 
directly involved in the inflammatory process. Caspase-1 is also involved in inflammasome formation and activation of cell necrosis or pyroptosis 
associated with the innate immune response. Serp-2 is encoded by myxomavirus and is a virulence factor. Serp-2 specifically binds to caspase-1, 
inhibiting cleavage of pro-IL-1β.
method: This study was designed to explore the functional role of the caspase-1/IL-1β signaling axis and Serp-2 treatment on IRI. Caspase-1-
deficient and wild-type (C57BL/6) mice underwent partial (70%) hepatic ischemia for 90mins as a model for IRI. Separate wild-type cohorts were 
treated with saline (500ul) vs. Serp-2 (100ng/g/day) intraperitoneal for 5 days. After 10 days of observation, hepatocellular injury and survival were 
assessed.
results: Caspase-1 deficiency improved survival up to 77.7%, compared to control mice with 42.9% survival (p=0.174). Serp-2 significantly 
ameliorated hepatocellular injury and increased survival by 87.5% compared to the control mice (p<0.046). Serp-2 treated specimens showed a 
significantly decreased degree of vacuolization (3.0 ± 0.58, p< 0.006), congestion (3.0 ± 0.54, p< 0.006) and necrosis (3.14 ± 0.14, p<0.0001) as 
well as decreased overall hepatic damage (Suzuki score 3.04 ± 0.381, p<0.0006) compared to control group (4.5, 4.4, 4.5 and 4.5 respectively).
conclusion: Serp-2 treatment or caspase-1 deficiency prevent ischemia reperfusion injury and improve survival after induced ischemia in a mouse 
IRI model. Caspase-1 signaling axis provides a novel therapeutic target for preventing ischemia reperfusion injury.
